82.1 F
San Fernando
Thursday, Mar 28, 2024

Study finds Amgen bone drug reduces fractures

Amgen Inc.’s experimental treatment for the bone-thinning disorder osteoporosis safely prevented spine and hip fractures, according to a study that may help win U.S. marketing clearance for the drug. A three-year trial of 7,800 women found that denosumab helped prevent more fractures of the vertebrae and hips compared with a placebo, Amgen reported in a regulatory filing today. Data showed denosumab was safe, with no statistically significant difference in adverse effects, Amgen said. For the full story visit www.latimes.com/business/la-fi-amgen17-2008sep17,0,5860145.story

Featured Articles

Related Articles